Literature DB >> 9141538

Circulating levels of insulin-like growth factor (IGF) binding protein-1 and -3 in aging men: relationships to insulin, glucose, IGF, and dehydroepiandrosterone sulfate levels and anthropometric measures.

C A Benbassat1, K C Maki, T G Unterman.   

Abstract

Reduced secretion of GH and production of insulin-like growth factor I (IGF-I) contribute to altered body composition in human aging. IGF-binding proteins (IGFBPs) are important modulators of IGF action, yet little is known regarding their role and regulation in aging. Accordingly, we measured levels of IGFBP-1, an important short term modulator of IGF bioavailability that is suppressed by insulin, and levels of IGFBP-3, the major circulating IGF carrier protein, and examined their relationships to insulin, glucose, IGF, and dehydroepiandrosterone sulfate levels and anthropometric measures in old (63-89 yr) and young (23-39 yr) men. Serum levels of IGFBP-1 were increased 3-fold in old vs. young men despite high insulin levels in elders. Nevertheless, IGFBP-1 and insulin levels correlated in old and young men (r = - 0.49; P < 0.002 and r = -0.42; P < 0.025), suggesting that insulin continues to play an important role in the regulation of IGFBP-1 in aging. Glucose levels also were significantly inversely related to IGFBP-1 in old and young men (r = 0.37; P = 0.02 and r = -0.49; P < 0.01), and this relationship was not accounted for by the effect of insulin. IGF-I levels were reduced by 33% in elders (P < 0.001) and correlated with IGFBP-1 levels among old (r = -0.40; P < 0.01), but not young, men, indicating that low GH secretion and/or IGF-I production may contribute to the elevation of IGFBP-1 levels in aging. IGFBP-3 levels were reduced among elders, but not to the same extent as IGF-I, resulting in a relative excess of IGFBP-3 in elders (IGFBP-3/IGF-I ratio, 20.1 +/- 0.9 vs. 15.4 +/- 1.0; P < 0.001). The IGFBP-3/IGF-I ratio correlated with IGF-I levels in young and old men (r = -0.79; P < 0.001 and r = -0.82; P < 0.001), indicating that diminished GH secretion also may contribute to a relative excess of IGFBP-3 among elders. Dehydroepiandrosterone sulfate levels were low in elders, but did not correlate with IGF, IGFBP, insulin, or glucose levels in either age group. Serum levels of IGFBP-1 (but not IGF-I or -II or IGFBP-3) correlated with body mass index and upper arm fat and muscle areas in elders. These relationships were accounted for by the effects of insulin, suggesting that regulation of IGFBP-1 by insulin may play a role in determining body composition in aging. We conclude that insulin remains an important determinant of IGFBP-1 levels in elders, that the fasting glucose level is also a significant determinant of IGFBP-1 in both old and young subjects, and that reduced secretion of GH may contribute to impaired anabolism in aging through multiple mechanisms, including reduced production of IGF-I and alterations in circulating levels of both IGFBP-1 and -3. These findings are consistent with the concept that alterations in IGFBP levels may contribute to changes in IGF bioavailability and body composition in aging.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9141538     DOI: 10.1210/jcem.82.5.3930

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  24 in total

Review 1.  Pathogenesis of postmenopausal osteoporosis.

Authors:  L G Raisz
Journal:  Rev Endocr Metab Disord       Date:  2001-01       Impact factor: 6.514

2.  Normal IGF-I and enhanced IGFBP-3 response to very low rhGH dose in patients with dilated cardiomyopathy.

Authors:  F Broglio; A Benso; E Arvat; G Aimaretti; C Gottero; R Granata; M F Boghen; M Bobbio; F Camanni; E Ghigo
Journal:  J Endocrinol Invest       Date:  2000-09       Impact factor: 4.256

Review 3.  Diabetic Kidney Disease in Older People with Type 2 Diabetes Mellitus: Improving Prevention and Treatment Options.

Authors:  Ahmed H Abdelhafiz
Journal:  Drugs Aging       Date:  2020-08       Impact factor: 3.923

Review 4.  Insulin-Like growth factor I: implications in aging.

Authors:  E Arvat; F Broglio; E Ghigo
Journal:  Drugs Aging       Date:  2000-01       Impact factor: 3.923

5.  Serum Insulin-Like Growth Factor 1 and the Risk of Ischemic Stroke: The Framingham Study.

Authors:  Hamidreza Saber; Jayandra J Himali; Alexa S Beiser; Ashkan Shoamanesh; Aleksandra Pikula; Ronenn Roubenoff; Jose R Romero; Carlos S Kase; Ramachandran S Vasan; Sudha Seshadri
Journal:  Stroke       Date:  2017-06-08       Impact factor: 7.914

Review 6.  Role of hormones in the pathogenesis and management of sarcopenia.

Authors:  Hosam K Kamel; Diana Maas; Edmund H Duthie
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

7.  Low IGF-1 levels are associated with cardiovascular risk factors in haemodialysis patients.

Authors:  Abdishakur M Abdulle; Michael P T Gillett; Samra Abouchacra; Sufyan M Sabri; Mona Al Rukhaimi; Enyioma N Obineche; Jaipaul Singh
Journal:  Mol Cell Biochem       Date:  2007-03-27       Impact factor: 3.396

8.  Influence of gender on serum growth hormone, insulin-like growth factor-I and its binding protein-3 during aging.

Authors:  Chiou-Meei Lin; Yeou-Lih Huang; Zu-Yau Lin
Journal:  Yonsei Med J       Date:  2009-06-24       Impact factor: 2.759

9.  Age-related DNA methylation in normal breast tissue and its relationship with invasive breast tumor methylation.

Authors:  Kevin C Johnson; Devin C Koestler; Chao Cheng; Brock C Christensen
Journal:  Epigenetics       Date:  2013-11-06       Impact factor: 4.528

Review 10.  Skeletal effects of growth hormone and insulin-like growth factor-I therapy.

Authors:  Richard C Lindsey; Subburaman Mohan
Journal:  Mol Cell Endocrinol       Date:  2015-09-25       Impact factor: 4.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.